Peer Review Committee for Cancer Drug Discovery (CDD)

Areas reviewed: Chemical studies dealing with the modification or development of drugs. Preclinical studies involving toxicity and effectiveness, and the development of drug delivery systems. Pharmacological studies, and studies involving nuclear magnetic resonance and crystallography, on the mechanisms of drug action, and the application of this information to drug design. Studies on the isolation, testing, and synthesis of natural therapeutic agents.

Coran Watanabe, Chair
Texas A&M University
College Station, TX

Joseph Kissil, PhD, Vice-Chair
Scripps Research Institute
Jupiter, FL

Kim Bannister, Stakeholder
Dallas, TX

Adrienne D. Cox, PhD
University of North Carolina
Chapel Hill, NC

M. Laird Forrest, PhD
University of Kansas
Lawrence, KS

Sandaruwan Geeganage, PhD
Eli Lilly and Company
Indianapolis, IN

Balazs Halmos, MD
Albert Einstein College of Medicine
Bronx, NY

Eric B. Haura, MD
Moffitt Cancer Center/University of South Florida
Tampa, FL

William G. Hawkins, MD
Washington University School of Medicine
St. Louis, MO

Seth Herzon, PhD
Yale University
New Haven, CT 

Geoffrey Hird, PhD
Liquidia Technologies, Inc.
Morrisville, NC

Mark Kester, PhD
University of Virginia/NanoSTAR Institute
Charlottesville, VA

Joerg Lahann, PhD
University of Michigan
Ann Arbor, MI

Tambre Leighn, Stakeholder

Samy Meroueh, PhD
Indiana University
Indianapolis, IN

Keykavous Parang, PharmD, PhD
Chapman University School of Pharmacy
Irvine, CA

David N. Wald, MD, PhD
Case Western Reserve University
Cleveland, OH

Susan Wee, PhD
Bristol-Myers Squibb Company
Princeton, NJ